Use of clinical decision-support system can improve HIV care

Use of clinical decision-support system can improve HIV care
Use of a clinical decision-support system appears to be beneficial in HIV care, with improvements noted in CD4 cell counts and clinic follow-up, according to a study published in the Dec. 4 issue of the Annals of Internal Medicine.

(HealthDay)—Use of a clinical decision-support system (CDSS) appears to be beneficial in HIV care, with improvements noted in CD4 cell counts and clinic follow-up, according to a study published in the Dec. 4 issue of the Annals of Internal Medicine.

Gregory K. Robbins, M.D., M.P.H., from Massachusetts General Hospital in Boston, and colleagues examined the efficacy of a CDSS in improving HIV outcomes in a involving 33 HIV care providers who followed 1,011 patients with HIV. In the , interactive computer alerts were generated for virologic failure, suboptimal follow-up, and abnormal test results, which facilitated rescheduling of appointments and repeat laboratory testing (FastTrack). Static alerts were received for the control group.

The researchers found that, in the intervention versus control group, the mean increase was significantly greater (0.0053 versus 0.0032 x 109 cells/L per month; P = 0.040) and the rate of six-month suboptimal follow-up was significantly lower (20.6 versus 30.1 events per 100 patient-years; P = 0.022). In the intervention group, the median time to next scheduled appointment was significantly shorter after a suboptimal follow-up alert (1.71 versus 3.48 months) and after a toxicity alert (2.79 versus >6 months). Adoption of the CDSS as part of standard care was supported by more than 90 percent of providers.

"The principles of FastTrack may readily transfer to other HIV clinical settings and inform the design of systems to support disease management and improve outcomes in HIV as well as other ," the authors write.

More information: Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

HIV status doesn't influence Hodgkin's lymphoma outcome

Oct 11, 2012

(HealthDay)—Despite more extensive disease and more adverse prognostic factors, HIV-positive patients with Hodgkin's lymphoma (HL) do not have worse outcomes when treated with doxorubicin, bleomycin, vinblastine, ...

Recommended for you

HIV lessons from the Mississippi Baby

19 minutes ago

(Medical Xpress)—The news in July that HIV had returned in a Mississippi toddler after a two-year treatment-free remission dashed the hopes of clinicians, HIV researchers and the public at large tantalized ...

User comments